🧬NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab for Drug Discovery
NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab for Dr…
TL;DR
NVIDIA and Eli Lilly announced a first-of-its-kind AI co-innovation lab focused on reinventing pharmaceutical R&D.
NVIDIA and Eli Lilly announced a first-of-its-kind AI co-innovation lab focused on reinventing pharmaceutical R&D. The two companies will invest up to $1 billion over five years in talent, compute infrastructure, and AI models built for biology.
Key Points
Up to $1 billion investment in talent, compute, and AI for biology
Five-year co-innovation lab focused on drug discovery
Pairs NVIDIA's BioNeMo platform with Lilly's proprietary data
Targets faster candidate identification and trial design
Why It Matters
Another top-tier pharma committing 10-figure budgets to AI signals that drug discovery is entering its foundation-model era.
Frequently Asked Questions
Why does this matter?
Another top-tier pharma committing 10-figure budgets to AI signals that drug discovery is entering its foundation-model era.
What happened?
NVIDIA and Eli Lilly announced a first-of-its-kind AI co-innovation lab focused on reinventing pharmaceutical R&D.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 3,097 builders reading daily.